TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06788327

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Protocol based on the best available evidence and to be used in all participants in both groups. The standard exercises protocol will consist of three postoperative rehabilitation phases: phase I (weeks 1 to 4), phase II (weeks 5 to 8) and phase III (weeks 9 to 12). Sessions will be held 2 times a week for 12 weeks. Each session will last 45 minutes and will consist of six exercises in the phase I, eight exercises in phase II, and eight exercises in phase III.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation
Description: Protocol based on the best available evidence and to be used in all participants in both groups. The standard exercises protocol will consist of three postoperative rehabilitation phases: phase I (weeks 1 to 4), phase II (weeks 5 to 8) and phase III (weeks 9 to 12). Sessions will be held 2 times a week for 12 weeks. Each session will last 45 minutes and will consist of six exercises in the phase I, eight exercises in phase II, and eight exercises in phase III.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy
Description: Participants will perform three exercises of the standard exercises protocol with BFRT. An auto-regulated portable BFRT SmartCuffs® 3.0 Pro system with a 17-inch long and 5-inch-wide cuff (Smart Tools Plus, United States), placed on the most proximal part of the arm, will be used. Each BFRT session will begin with a maximal occlusion test to personalize the occlusion pressure to the participant. The limb occlusion pressure (LOP) will be set at 50% of the maximum occlusion pressure in the first stage and 60% in stages II and III. The participant will perform 75 repetitions per BFRT exercise divided into 4 sets (30, 15, 15, and 15 repetitions). The load intensity during the BFRT exercises will be set near to 3 out of 10 on the Borg's CR10 scale (weak), which corresponds to 30% of a 1RM effort. After each exercise, the cuff will be deflated, and the patient will rest for two minutes.
Study: NCT04629729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent
Study: NCT06788340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PK-model to decide when to dose Vedolizumab and Ustekinumab
Description: the pharmacokinetic model will include information about inflammatory parameters both in blood- and fecal samples, as well as weight, sex, previous treatments and drug concentration.
Study: NCT06788535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-124 evuzamitide
Description: I-124 evuzamitide, single dose imaging agent, administered intravenously.
Study: NCT06789224

Intervention type: DEVICE
Group type: OTHER
Intervention: CATUVAB
Description: inducing of aggreation of tumor cells and immune cells via trifunctional antibody and removal of aggregates
Study: NCT05073068

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No exercise
Study: NCT04629729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent
Study: NCT06788158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Incobotulinum Toxin A
Description: will be administered 2 ampoules (200 IU) of Incobotulinum toxin , injectable solution presentation 100 IU ampoule with powder diluted in 1 ml of 0.9% saline solution in a single application at 4 points, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid
Description: Program in which 2 ml of dexamethasone will be administered in an 8 mg/2 ml ampoule diluted in 2 ml of lidocaine injectable solution in a 50 ml bottle (20 mg/ml) in a single application at 1 point, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).
Study: NCT06790108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence device
Description: This AI device can provide prompts for standard sites of pancreatic scans and anatomical structures. It may also suggest the next operation methods.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Artificial intelligence device
Description: This AI device can provide prompts for standard sites of pancreatic scans and anatomical structures. It may also suggest the next operation methods.
Study: NCT06789081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCAR1
Description: GCAR 1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (CAR) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic B (GPNMB).
Study: NCT06788210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiprofessional Geriatric Emergency Team applied front-door CGA to identify patients who require inpatient care and those who can safely be discharged.
Description: In comparison to the precedent studies, this project is characterised by some innovative aspects as regards to the design of intervention:~1. the participation of both a geriatrician and a nurse expert in transitional care, with the consultancy of a social worker when needed, in the management of the elderly patient within ED, adds to the project a greater operational capacity of the multidimensional assessment (CGA) of planning the best care setting for the patient.~2. The proposed CGA model is complete in the analysis of the different domains (social, clinical, functional, cognitive-affective) and achievable in this particular urgent setting.~3. The program examines, unlike other studies, much more variables that can help to define the effectiveness of the intervention.~4. The involvement in the network program of three main hospitals of the Emilia Romagna with a pool of elderly patients afferent to ED of about 20,000 elderly/year per hospital (2019 data prior of Sars Cov2 pandemic)
Study: NCT06788964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine and Rituximab
Description: Patients will receive Lonca-R intravenously for 1-6 cycles (every 21 days) prior to standard of care CAR-T cell therapy.
Study: NCT05676047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation
Description: A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
Study: NCT06789393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive dexmedetomidine (0.5 mcg/kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Penile block with bupivacaine 0.25% (0.2 ml/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Penile block with bupivacaine 0.25% (0.2 ml/kg)
Study: NCT06789887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: Written Exposure Therapy (WET) is a 5-session, trauma-focused intervention in which individuals write about their traumatic experience following scripted instructions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment as usual (TAU) will be available to all patient participants. Treatment as usual may include various forms of psychotherapy and or medication management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Treatment as usual (TAU) will be available to all patient participants. Treatment as usual may include various forms of psychotherapy and or medication management.
Study: NCT04629729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent
Study: NCT06788626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Description: 0.5mg semaglutide injection before and 1 week after endovascular treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard medical management
Study: NCT06790186

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Perceive, Recall, Plan and Perform intervention Interventions:
Description: The PRPP is a standardized system which determines the impact of information processing on performance of everyday activities. It is a method for assessment of performance mastery, and efficient use of cognitive strategies, as well as a model of intervention to train mastery and cognitive strategy use, in everyday activities. The PRPP assess task performance mastery, as well as cognitive strategy application
Study: NCT06788184

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality (VR) Game for Auditory Processing
Description: The Virtual Reality (VR) Game is a novel auditory rehabilitation tool designed to enhance central auditory processing skills in children with cochlear implants. This intervention features a restaurant simulation environment where participants perform auditory tasks such as identifying verbal orders, recognizing speech in noisy environments, and matching auditory cues to visual inputs.~Dosage Form: Virtual reality sessions conducted through a VR headset (Oculus Meta Quest 3).~Frequency: Once per week. Duration per Session: 30 minutes per session. Total Duration: Four weeks (4 sessions). Complexity Levels: Tasks increase in complexity over time, starting with simple auditory cues in quiet environments and progressing to more challenging scenarios involving background noise and multitasking.~The VR game is specifically designed to replicate real-world auditory challenges in a controlled and engaging virtual environment, providing participants with tailored tasks to improve auditory atten

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Auditory Rehabilitation
Description: Name: Traditional Auditory Rehabilitation~Description:~Participants will continue the standard auditory rehabilitation program they are already receiving at their registered rehabilitation centers, focusing on improving auditory processing skills. This program includes:~Session Duration: 30 minutes per session Frequency: Once per week Total Duration: 4 weeks (4 sessions in total)~Components:~Exercises to enhance auditory attention Activities to improve auditory memory

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Auditory Rehabilitation
Description: Name: Traditional Auditory Rehabilitation~Description:~Participants will continue the standard auditory rehabilitation program they are already receiving at their registered rehabilitation centers, focusing on improving auditory processing skills. This program includes:~Session Duration: 30 minutes per session Frequency: Once per week Total Duration: 4 weeks (4 sessions in total)~Components:~Exercises to enhance auditory attention Activities to improve auditory memory
Study: NCT06788587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDX-01 plus TAU
Description: Participants receive once daily LDX-01 for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus TAU
Description: Participants receive once daily LDX-01-matched placebo for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25).
Study: NCT04604977

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness
Description: Patients are followed with a standardized program including: education and support for behavioral measures, behavioral sessions, by mindfulness, once per week for 45 minutes for 6 weeks which usually delivered in groups of 4 - 8 patients.
Study: NCT04629729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier
Study: NCT06146972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod 25mg bid + tofacitinib 5mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod 25mg bid + tofacitinib 5mg bid
Study: NCT05967715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: high intensity interval training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: VSL#3# Probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Probiotic Placebo
Study: NCT06789601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informatics system for eligibility monitoring
Description: A daily automated data query of eligible subjects will collect EHR data, and our informatics system will be run on these data behind our institution's secure firewall. The daily list of subjects identified by the informatics system as having a new irAE will be accessed by the Alliance irAE biorespository study team at Dana-Farber/Brigham Cancer Center for review.
Study: NCT04629729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lympho-conditioning agent
Study: NCT06109415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1 g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1 g

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation
Study: NCT06565221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat and negative pressure
Description: Heat and negative pressure applied to the feet
Study: NCT05398770

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D supplementation (30 µg/d)
Description: The participants will be instructed to take the tablets (vitamin D or placebo) once a day 4 weeks prior to the onset of the non-surgical periodontal treatment (NSPT), and to continue for two weeks after their first NSPT, altogether 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (30 µg/d)
Description: The participants will be instructed to take the tablets (vitamin D or placebo) once a day 4 weeks prior to the onset of the non-surgical periodontal treatment (NSPT), and to continue for two weeks after their first NSPT, altogether 6 weeks.
Study: NCT06789601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard eligibility monitoring
Description: Reporting of an eligible event to the biorepository study staff by the treating clinician and EHR review by the study staff.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard eligibility monitoring
Description: Reporting of an eligible event to the biorepository study staff by the treating clinician and EHR review by the study staff.
Study: NCT06790004

Intervention type: PROCEDURE
Intervention: Laparotomy
Description: Open Surgery

Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: Minimally invasive surgery
Study: NCT06050915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-3405
Description: DISC-3405 is administered as a single dose IV infusion or subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-3405
Description: DISC-3405 is administered in multiple ascending doses as an IV infusion or subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as a single dose IV infusion or subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered in multiple ascending doses as an IV infusion or subcutaneous injection
Study: NCT06657183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alio Smart Patch™
Description: Alio Smart Patch is a non-invasive wearable biosensor that combines a unique, multi-sensor, wearable device with a provided- based portal to track sequentially the participant's physiologic, hematologic and electrolyte data. It works in conjunction with a home hub data relay system and an end-to-end cloud software data path. The system has been developed to enable home monitoring for multiple key metrics by healthcare provider caring for participants.~Enhanced Care Management (ECM) is a comprehensive, system-centric approach crafted to bridge the latent gaps in traditional care paradigms. ECM provides an exhaustive review of a participant's medical history and their personalized social needs, addressing both in a cohesive, participant-focused strategy.~This intervention couples Quantify Remote Care's Enhanced Care Management with the Alio Smart Patch technology.
Study: NCT06527040

Intervention type: OTHER
Intervention: Opioid Transitions Clinical Decision Support (CDS)
Description: Clinical decision support in the form of an electronic health record (EHR) integrated, provider-facing alert suggesting (a) the patient is transitioning to a new phase of opioid therapy and (b) the provider should review patient pain data and pain management goals as suggested by Center for Disease Control and Prevention (CDC) guidelines.
Study: NCT06788301

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior Alveolar Nerve Block
Description: local anesthesia administration (inferior alveolar nerve block)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior Alveolar Nerve Block
Description: local anesthesia administration (inferior alveolar nerve block)
Study: NCT05560724

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Anodal stimulation or sham

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Anodal stimulation or sham

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Anodal stimulation or sham
Study: NCT04629729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lympho-conditioning agent